Private Equity Week Wire

SAN FRANCISCO — Groxis, Inc., a next generation information and
knowledge management software company today announced the addition of R.J. Pittman
as CEO and member of the company’s founding team and board of directors. Mr. Pittman
is founder and Managing Director of Venture Factory Partners, a San Francisco-based
venture capital firm. He has led investments in several technology companies including
Cosine Communications, Method Networks, Startups, Inc., Privacy Right, and Aravo
Solutions. Mr. Pittman brings over 15 years experience with building and operating Internet
software and service companies to Groxis, including recent roles as CEO of DCTI, and
CEO of Broadway.com, Inc., for both of which he was also a founder. At Groxis, he will be
responsible for overall corporate strategy, and for building the necessary infrastructure to
successfully deploy its new software platform.

WALTHAM, MA — InfoLibria, Inc., a leading provider
of Internet infrastructure solutions for service providers and enterprises
deploying content delivery networks (CDNs), today announced that it has
completed a $41 million round of funding that will finance the company’s
growth on its path to profitability. Led by Mellon Ventures, the financing
includes current InfoLibria investors such as Adams Capital, Kemper Ventures,
Patricof and Company, Sandler Capital Partners, Madison Dearborn, GE Capital,
Telesoft Partners IA, and Tudor Private Equity Fund, along with new
investments from StarVest Partners, Mitsubishi, and private investors.

DUBLIN — Prediction Dynamics,
the Systematic Trading and Risk Management Software Company, has today announced
the successful completion of its first round funding. The 650,000 Euros investment was
made by Ireland’s leading independent venture capital management company, ACT
Venture Capital and will enable the company to pursue its aggressive growth plans and to
bring its Crucible(TM) product to market later this year.

BEDFORD, MA – NitroMed Inc., a pioneer in the development
and commercialization of Nitric Oxide (NO)-enhanced medicines, today
announced that it has raised a private financing round of $31.4 million,
primarily to continue late-stage clinical and regulatory development of its
lead product, BiDil